| Literature DB >> 28979182 |
Angelo Corti1, Anna Maria Gasparri2, Michela Ghitti2, Angelina Sacchi1, Francesco Sudati2, Martina Fiocchi2, Valentina Buttiglione2, Laura Perani2, Alessandro Gori3, Silvia Valtorta2,4, Rosa Maria Moresco2,4, Fabio Pastorino5, Mirco Ponzoni5, Giovanna Musco2, Flavio Curnis2.
Abstract
NGR (asparagine-glycine-arginine) is a tumor vasculature-homing peptide motif widely used for the functionalization of drugs, nanomaterials and imaging compounds for cancer treatment and diagnosis. Unfortunately, this motif has a strong propensity to undergo rapid deamidation. This reaction, which converts NGR into isoDGR, is associated with receptor switching from CD13 to integrins, with potentially important manufacturing, pharmacological and toxicological implications. It is found that glycine N-methylation of NGR-tagged nanocarriers completely prevents asparagine deamidation without impairing CD13 recognition. Studies in animal models have shown that the methylated NGR motif can be exploited for delivering radiolabeled compounds and nanocarriers, such as tumor necrosis factor-α (TNF)-bearing nanogold and liposomal doxorubicin, to tumors with improved selectivity. These findings suggest that this NGR derivative is a stable and efficient tumor-homing ligand that can be used for delivering functional nanomaterials to tumor vasculature.Entities:
Keywords: N-methylglycine; deamidation; enzyme; molecular docking; peptides
Year: 2017 PMID: 28979182 PMCID: PMC5624507 DOI: 10.1002/adfm.201701245
Source DB: PubMed Journal: Adv Funct Mater ISSN: 1616-301X Impact factor: 18.808